J Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. 1997. Advanced Drug Delivery Reviews. 46 (1–3): 3–26. doi:10.1016/S0169-409X(00)00129-0. [3] Wang Sheng, Che Tao, Levit Anat, Shoichet Brian K, Wacker Danieal, and Roth Bryan L. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. 2018 Mar 8;555(7695):269-273. doi: 10.1038/nature25758. Epub 2018 Jan 24. PMID: 29466326; PMCID: PMC5843546. [2] Nathan Brown, Marco Fiscato, Marwin Segler, and Alain Vaucher. GuacaMol: Benchmarking Models for de Novo Molecular Design. Journal of Chemical Information and Modeling. 2019. 59. 10.1021/acs.jcim.8b00839. [4] Hachiro Sugimoto, Hiroo Ogura, Yasuo Arai, Youichi Iimura, and Yoshiharu Yamanishi. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Japanese Journal of Pharmacology, 89(1):7–20, 2002. ISSN 0021-5198. doi: https://doi.org/10.1254/jjp.89.7. URL: https://www.sciencedirect.com/science/article/pii/S0021519819301428. 8 Experiments • Lipinski’s Rule of 5 Distribution: Evaluation of the potential of generated compounds from our framework to be orally active or viable drugs 1. • Guacamol’s Goal-directed Benchmark: Standard benchmarking for de novo molecular design comprising of 13 tasks including rediscovery, similarity and multi-objective optimization 2. • DRD2 Actives Generation: Generation of active compounds on the Dopamine Receptor 2 target, a primary target for drugs used to treat schizophrenia and Parkinson’s disease 3. • Donepezil Rediscovery: An attempt to rediscover and obtain possible synthetic paths for donepezil, a known acetylcholinesterase inhibitor 4. • Patent Compounds Rediscovery: An attempt to rediscover and obtain synthetic paths for 3 selected patented compounds not present in public training datasets.